These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 25410891)

  • 1. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio.
    Sistonen J; Büchel B; Froehlich TK; Kummer D; Fontana S; Joerger M; van Kuilenburg AB; Largiadèr CR
    Pharmacogenomics; 2014 Sep; 15(13):1653-66. PubMed ID: 25410891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dihydrouracil/uracil ratio in plasma, clinical and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal cancer patients treated with 5-fluorouracil.
    Ben Fredj R; Gross E; Ben Ahmed S; Hassine H; Saguem S
    Pathol Biol (Paris); 2009 Sep; 57(6):470-6. PubMed ID: 18619742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A simple and rapid high-performance liquid chromatographic (HPLC) method for 5-fluorouracil (5-FU) assay in plasma and possible detection of patients with impaired dihydropyrimidine dehydrogenase (DPD) activity.
    Ciccolini J; Mercier C; Blachon MF; Favre R; Durand A; Lacarelle B
    J Clin Pharm Ther; 2004 Aug; 29(4):307-15. PubMed ID: 15271097
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous plasma and salivary uracil to dihydrouracil ratios and DPYD genotyping as predictors of severe fluoropyrimidine toxicity in patients with gastrointestinal malignancies.
    Galarza AF; Linden R; Antunes MV; Hahn RZ; Raymundo S; da Silva AC; Staggemeier R; Spilki FR; Schwartsmann G
    Clin Biochem; 2016 Nov; 49(16-17):1221-1226. PubMed ID: 27399164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indirect assessment of dihydropyrimidine dehydrogenase activity in cats.
    Saba CF; Schmiedt CW; Freeman KG; Edwards GL
    Vet Comp Oncol; 2013 Dec; 11(4):265-71. PubMed ID: 24007333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comprehensive population-based study comparing the phenotype and genotype in a pretherapeutic screen of dihydropyrimidine dehydrogenase deficiency.
    Pallet N; Hamdane S; Garinet S; Blons H; Zaanan A; Paillaud E; Taieb J; Laprevote O; Loriot MA; Narjoz C
    Br J Cancer; 2020 Sep; 123(5):811-818. PubMed ID: 32595208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
    Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
    Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DPD functional tests in plasma, fresh saliva and dried saliva samples as predictors of 5-fluorouracil exposure and occurrence of drug-related severe toxicity.
    Neto OV; Raymundo S; Franzoi MA; do Carmo Artmann A; Tegner M; Müller VV; Hahn RZ; Alves GV; Schwartsmann G; Linden R; Antunes MV
    Clin Biochem; 2018 Jun; 56():18-25. PubMed ID: 29625079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypermethylation of the DPYD promoter region is not a major predictor of severe toxicity in 5-fluorouracil based chemotherapy.
    Amstutz U; Farese S; Aebi S; Largiadèr CR
    J Exp Clin Cancer Res; 2008 Oct; 27(1):54. PubMed ID: 18937829
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Methylation of the DPYD promoter: an alternative mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients.
    Ezzeldin HH; Lee AM; Mattison LK; Diasio RB
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8699-705. PubMed ID: 16361556
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Denaturing high performance liquid chromatography analysis of the DPYD gene in patients with lethal 5-fluorouracil toxicity.
    Ezzeldin H; Johnson MR; Okamoto Y; Diasio R
    Clin Cancer Res; 2003 Aug; 9(8):3021-8. PubMed ID: 12912951
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of 5-fluorouracil-induced early severe toxicity by pre-therapeutic dihydropyrimidine dehydrogenase deficiency screening: Assessment of a multiparametric approach.
    Boisdron-Celle M; Capitain O; Faroux R; Borg C; Metges JP; Galais MP; Kaassis M; Bennouna J; Bouhier-Leporrier K; Francois E; Baumgaertner I; Guerin-Meyer V; Cojocarasu O; Roemer-Becuwe C; Stampfli C; Rosenfeld L; Lecompte T; Berger V; Morel A; Gamelin E
    Semin Oncol; 2017 Feb; 44(1):13-23. PubMed ID: 28395758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Review of methods for determination of dihydropyrimidine dehydrogenase and possible application in screening previous chemotheraphy with 5-fluorouracil].
    Ostapowicz A; Dołegowska B
    Przegl Lek; 2012; 69(9):694-7. PubMed ID: 23401991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients.
    Zhou ZW; Wang GQ; Wan de S; Lu ZH; Chen YB; Li S; Chen G; Pan ZZ
    Chemotherapy; 2007; 53(2):127-31. PubMed ID: 17308379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian rhythm of dihydrouracil/uracil ratios in biological fluids: a potential biomarker for dihydropyrimidine dehydrogenase levels.
    Jiang H; Lu J; Ji J
    Br J Pharmacol; 2004 Feb; 141(4):616-23. PubMed ID: 14744810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phenotypic and clinical implications of variants in the dihydropyrimidine dehydrogenase gene.
    Kuilenburg ABPV; Meijer J; Tanck MWT; Dobritzsch D; Zoetekouw L; Dekkers LL; Roelofsen J; Meinsma R; Wymenga M; Kulik W; Büchel B; Hennekam RCM; Largiadèr CR
    Biochim Biophys Acta; 2016 Apr; 1862(4):754-762. PubMed ID: 26804652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Haplotype structure defines effects of common DPYD variants c.85T > C (rs1801265) and c.496A > G (rs2297595) on dihydropyrimidine dehydrogenase activity: Implication for 5-fluorouracil toxicity.
    Hamzic S; Schärer D; Offer SM; Meulendijks D; Nakas C; Diasio RB; Fontana S; Wehrli M; Schürch S; Amstutz U; Largiadèr CR
    Br J Clin Pharmacol; 2021 Aug; 87(8):3234-3243. PubMed ID: 33491253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genotyping of a family with a novel deleterious DPYD mutation supports the pretherapeutic screening of DPD deficiency with dihydrouracil/uracil ratio.
    Thomas F; Hennebelle I; Delmas C; Lochon I; Dhelens C; Garnier Tixidre C; Bonadona A; Penel N; Goncalves A; Delord JP; Toulas C; Chatelut E
    Clin Pharmacol Ther; 2016 Feb; 99(2):235-42. PubMed ID: 26265035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between the urinary dihydrouracil-uracil ratio and the 5-FU plasma concentration in patients treated with oral 5-FU analogs.
    Nakayama Y; Matsumoto K; Inoue Y; Katsuki T; Kadowaki K; Shibao K; Tsurudome Y; Hirata K; Sako T; Nagata N; Itoh H
    Anticancer Res; 2006; 26(5B):3983-8. PubMed ID: 17094430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Can we identify patients carrying targeted deleterious
    Launay M; Raymond L; Guitton J; Loriot MA; Chatelut E; Haufroid V; Thomas F; Etienne-Grimaldi MC
    Clin Chem Lab Med; 2024 Nov; 62(12):2415-2424. PubMed ID: 38896022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.